Auven Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Delray Beach FL United States (2007)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2014
NCT02329743
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Ocular Therapeutics SARL

Active Ingredients

Drugs in Phase 3 Trials (1)

cyclosporine (sandimmune) (1 trial)

Drugs in Phase 2 Trials (1)

rx-10045 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 2)

Dry Eye Syndromes (Phase 3)

Inflammation (Phase 2)

Keratoconjunctivitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2